echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Focus on rare disease "thalassemia": FDA awards Mitapivat orphan drug title

    Focus on rare disease "thalassemia": FDA awards Mitapivat orphan drug title

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical company Agios announced today that the U.SFood and Drug Administration, theAdministration of(
    FDA) has awarded acetone acid kinase-R (PKR) activator mitapivat for the treatment of thalassemia orphan drug titleMitapivat is a research small molecular deconstruction activator of wild and multi-mutant PKRDr Chris Bowden, Chief Medical Officer of Agios, said: "The acquisition of the orphan drug designation is an important milestone for AgiosWe will continue to promote Mitapivat therapy for thalassemia patientsThe latest data from the Mitapivat treatment of alpha and beta thalassemia II will be presented at the upcoming annual meeting of the European Society of Hematology (EHA)thalassemias is an inherited blood disorder that causes hemoglobin synthesis disorders, and its symptoms can vary according to type, to varying degrees from asymptomatic to severeCommonly thalassemia is accompanied by a typical symptom of anemia, namely low levels of red blood cellsAnemia can lead to feelings of fatigue and pale skin tone, as well as bone disease, spleen swelling, jaundice, dark urine, andgrowth delays in children
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.